Moderna’s Bid For Second COVID Vaccine Booster Spans Broader Age Group Than Pfizer/BioNTech
Executive Summary
US FDA advisory committee will meet in April to discuss whether and when boosters may be needed and for whom; Moderna seeks authorization for second booster dose in everyone ≥18 years, while Pfizer/BioNTech have limited their request to individuals ≥65 years.
You may also be interested in...
Moderna’s COVID-19 Second Booster Authorization Largely Thanks To Pfizer/BioNTech Data
Safety and effectiveness of an mRNA-1273 second booster dose was inferred in large part by extrapolation from reported evidence following use of the Pfizer/BioNTech COVID-19 vaccine in individuals 60 years and older in Israel, FDA review memos show.
US FDA Bypasses Adcomm In Authorizing Second COVID Booster Because Decision ‘Straight-Forward’
Advisory committee member says FDA's decision to authorize extra shots of Pfizer and Moderna vaccines for those 50 and older was a short-term solution and that VRBPAC should prioritize long-term issues related to the coronavirus.
US FDA ‘Actively Working’ To Fill Vaccine Leadership Positions Ahead Of Next Round Of COVID Reviews
As decisions on additional boosters and childhood inoculations loom, CBER Director Peter Marks is still heading the vaccines division on an acting basis since the departures of Marion Gruber and Philip Krause last year. Who might succeed them?